Blood/liquid biopsy-based biomarkers for the most accurate early detection of cancer are still in the early phases of development. Before these types of biomarkers/tests can be used in the clinical setting, various clinical and preclinical issues (e.g. detection sensitivity) need to be addressed. This session discusses latest advancements in the development of blood-based biomarkers and describes clinical study programs in which they are implemented, including the limitations and challenges that need to be overcome before the translation of their use for clinical purpose will be a reality.
Anne-Renee Hartman, MD, is Vice President of Clinical Development at GRAIL. Prior to GRAIL, Anne-Renee was the Senior Vice President of Clinical Development at Myriad Genetics, where she led the development of several commercialized diagnostics in oncology. Anne-Renee was previously an Assistant Professor of Medicine at The Dana Farber Cancer Institute. She completed her oncology fellowship at Stanford where she helped set up the cancer genetics clinic. Anne-Renee holds a BS in Molecular Biology from Princeton University, an MD from The University of Michigan, and completed her residency in Internal Medicine at The University of Chicago.
Dr. Kalluri’s research is broadly interested in the study of cell and tissue microenvironment and its impact on cancer progression and metastasis. Kalluri received his Ph.D. in Biochemistry and Molecular Biology from the University of Kansas Medical Center and his M.D. from Brown University Medical School. In 1997 he moved to Harvard Medical School as assistant professor of medicine and as a faculty based in the Department of Medicine at the Beth Israel Deaconess Medical Center. He later was appointed the chief of the Division of Matrix Biology and promoted to professor of medicine at Harvard Medical School. In 2012 Dr. Kalluri moved to The University of Texas MD Anderson Cancer Center as Professor and Chairman of the Department of Cancer Biology and Director of the Metastasis Research Center, and he currently holds the RE Bob Smith Distinguished Chair for Cancer Research.
The major focus of Dr. Alizadeh’s research group is to attain a better understanding of the initiation, maintenance, and progression of lymphoid tumors, and their response to existing and novel therapies toward improving current treatment strategies. In this effort, they employ tools from functional genomics, computational biology, molecular genetics, and mouse models. They hope to apply this knowledge towards the design of clinical trials in the treatment of patients with lymphoma, leukemia, and myeloma.